Published in J Clin Oncol on January 27, 2005
Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 3.61
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Measuring the performance of markers for guiding treatment decisions. Ann Intern Med (2011) 1.95
Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity (2013) 1.75
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol (2010) 1.68
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer (2009) 1.68
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer (2008) 1.55
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer (2008) 1.43
PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med (2012) 1.38
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res (2008) 1.35
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One (2008) 1.31
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst (2009) 1.31
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol (2011) 1.31
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem (2012) 1.26
Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity (2015) 1.26
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
EGFR Signaling in Colorectal Carcinoma. Patholog Res Int (2011) 1.20
Colorectal carcinogenesis--update and perspectives. World J Gastroenterol (2014) 1.19
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res (2013) 1.18
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer (2009) 1.18
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res (2006) 1.18
KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci (2011) 1.17
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer (2006) 1.14
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev (2010) 1.13
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med (2010) 1.13
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer (2008) 1.13
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn (2008) 1.11
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med (2008) 1.07
EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer (2011) 1.06
Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov (2010) 1.02
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia (2008) 1.02
Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol (2013) 1.01
Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res (2012) 1.01
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des (2008) 1.00
Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov (2011) 1.00
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer (2009) 0.99
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs (2009) 0.99
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer (2007) 0.99
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99
Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther (2013) 0.99
Erlotinib in the treatment of advanced pancreatic cancer. Biologics (2008) 0.98
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol (2013) 0.98
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer (2009) 0.98
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol (2008) 0.98
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer (2013) 0.98
Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol (2011) 0.97
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther (2013) 0.97
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol (2010) 0.96
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer (2006) 0.95
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer (2010) 0.95
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics (2009) 0.95
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol (2008) 0.95
A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. Trials (2012) 0.95
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.94
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch (2006) 0.93
Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther (2010) 0.93
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol (2007) 0.93
Management of stage IV rectal cancer: palliative options. World J Gastroenterol (2011) 0.93
Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol (2010) 0.92
G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasis. Front Neuroendocrinol (2011) 0.92
Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res (2011) 0.92
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol (2008) 0.92
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol (2014) 0.92
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol (2010) 0.91
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
[Delayed appearance of symptoms in immediate hypersensitivity: type I sensitization to galactose-α-1,3-galactose]. Hautarzt (2012) 0.91
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Primary care physicians who treat blacks and whites. N Engl J Med (2004) 12.23
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Care patterns in Medicare and their implications for pay for performance. N Engl J Med (2007) 6.74
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Using navigators to improve care of underserved patients: current practices and approaches. Cancer (2005) 5.56
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist (2013) 4.33
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA (2009) 4.04
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol (2006) 3.83
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med (2009) 3.59
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
Delivery of preventive services to older adults by primary care physicians. JAMA (2005) 3.53
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med (2003) 3.01
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum (2004) 2.52
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27